Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Urethral Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00002684

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Procedure: therapeutic conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT00002852

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Phase 1

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003105

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00006245

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005599

Locations: 🇺🇸
Albert Einstein Clinical Cancer Center, Bronx, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020449

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

Phase 3

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 608

Registration Number: NCT00022191

Locations: 🇺🇸
Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

and more 231 locations

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Recurrent Endometrial Carcinoma
Recurrent Gastric Cancer
Recurrent Non-small Cell Lung Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Small Cell Lung Cancer

Interventions: Biological: trastuzumab
Drug: paclitaxel
Biological: recombinant interleukin-12

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00028535

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: suramin
Drug: carboplatin
Drug: paclitaxel
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT00006929

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

Phase 3

Completed

Conditions: HER2-negative Breast Cancer
HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: paclitaxel
Biological: trastuzumab
Procedure: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 580

Registration Number: NCT00003440

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy